# Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

> **NCT00450203** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Professor David Cunningham** · enrollment: 1103 (estimated)

## Conditions studied

- Oesophagogastric Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** Epirubicin
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy
- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT00450203
- **Lead sponsor:** Professor David Cunningham
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 1103 (ESTIMATED)
- **Last updated:** 2016-12-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450203, "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00450203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*